Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients
Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients
复制标题
DOI：
10.1016/j.ajog.2010.04.019
复制
发表时间：
2010-10-01
影响因子：
9.8
通讯作者：
Chan, John K.
中科院分区：
文献类型：
--
作者：
Cohen, Joshua G.;Kapp, Daniel S.;Chan, John K.
目的：为了确定与神经内分泌小细胞宫颈癌patients.Study Design生存相关的临床病理因素：患者被确定从文献回顾与另外52例来自四家医院。结果：188例患者中，I-IIA期135例，IIB-IVA期45例，IVB期8例。55.3%接受手术，16.0%接受放化疗，12.8%接受放疗，3.2%接受单纯化疗。I-IIA、IIB-IVA和IVB期患者的5年疾病特异性生存率分别为36.8%、9.8%和0%（P <0.001）。与未接受化疗的患者相比，辅助化疗或放化疗与IIB-IVA期疾病患者的生存率改善相关（17.8% vs 6.0%; P = 0.04）。多变量分析，早期疾病和使用化疗或放化疗是独立的预后因素，为改善survival.CONCLUSION：辅助化疗或放化疗的使用与高生存率的小细胞宫颈癌患者。
OBJECTIVE: To determine the clinicopathologic factors associated with survival in neuroendocrine small cell cervical cancer patients.STUDY DESIGN: Patients were identified from a review of literature with an additional 52 patients from four hospitals. Kaplan-Meier and Cox regression methods were used for analyses.RESULTS: Of 188 patients, 135 had stages I-IIA, 45 stages IIB-IVA, and 8 stage IVB disease. A total of 55.3% underwent surgery, 16.0% had chemoradiation, 12.8% radiation, and 3.2% chemotherapy alone. The 5-year disease-specific survival in stage I-IIA, IIB-IVA, and IVB disease was 36.8%, 9.8%, and 0%, respectively (P < .001). Adjuvant chemotherapy or chemoradiation was associated with improved survival in patients with stages IIB-IVA disease compared with those who did not receive chemotherapy (17.8% vs 6.0%; P = .04). On multivariable analysis, early-stage disease and use of chemotherapy or chemoradiation were independent prognostic factors for improved survival.CONCLUSION: Use of adjuvant chemotherapy or chemoradiation was associated with higher survival in small cell cervical cancer patients.